What are the recommended dosing, contraindications, and drug interactions for sildenafil (Viagra) and other PDE‑5 inhibitors?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Sildenafil (Viagra) and PDE5 Inhibitors: Dosing, Contraindications, and Drug Interactions

For most patients with erectile dysfunction, start with sildenafil 50 mg taken approximately 1 hour before sexual activity, with the absolute contraindication being concurrent nitrate use, and dose adjustments required for patients over 65, those with hepatic/renal impairment, or those taking potent CYP3A4 inhibitors. 1

Recommended Dosing

Standard Dosing Protocol

  • Initial dose: 50 mg taken 1 hour before sexual activity 1
  • Timing window: Can be taken anywhere from 4 hours to 0.5 hours before sexual activity 1
  • Dose titration: May increase to maximum 100 mg or decrease to 25 mg based on effectiveness and tolerability 1
  • Maximum frequency: Once per day 1

Dose Adjustments Required

Start with 25 mg in these populations 1:

  • Age >65 years (40% increase in drug exposure)
  • Hepatic impairment such as cirrhosis (80% increase in exposure)
  • Severe renal impairment (creatinine clearance <30 mL/min; 100% increase in exposure)
  • Concurrent use of potent CYP3A4 inhibitors:
    • Erythromycin (182% increase in exposure)
    • Saquinavir (210% increase)
    • Ketoconazole or itraconazole

Special ritonavir dosing: Maximum single dose of 25 mg in a 48-hour period due to 11-fold increase in drug exposure 1

Other PDE5 Inhibitors

All four FDA-approved PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) demonstrate similar efficacy in the general ED population 2. Selection depends primarily on intercourse frequency and patient preference 3:

  • Tadalafil: Unique longer half-life allows daily dosing option; produces same efficacy whether taken on-demand or daily 2
  • Vardenafil and avanafil: Similar pharmacokinetic profiles to sildenafil 3

Absolute Contraindications

Nitrates - The Critical Contraindication

Concurrent use of PDE5 inhibitors with any nitrate or nitric oxide donor is absolutely contraindicated 1. This combination causes severe, potentially life-threatening hypotension 1.

  • No nitrates within 24 hours of sildenafil use 4
  • Includes: glyceryl trinitrate, isosorbide dinitrate, and all other organic nitrates 5

Other Absolute Contraindications

  • Allergy to the active ingredient 6
  • Retinitis pigmentosa 6
  • Vardenafil-specific: Type 1A antiarrhythmics (quinidine, procainamide) or Type 3 antiarrhythmics (sotalol, amiodarone) 7

Relative Contraindications and Precautions

Cardiovascular Considerations

  • Unstable angina pectoris 5
  • Recent myocardial infarction or stroke (within 6 months) 5
  • Uncontrolled hypertension 5
  • Cardiac failure with impaired cardiac reserve 5
  • Severe aortic stenosis 4
  • Hypertrophic obstructive cardiomyopathy (HOCM) 4

Important clinical context: ED itself is a significant independent risk marker for cardiovascular disease, as strong a predictor as smoking or family history of MI 2. The Princeton Consensus guidelines should guide cardiovascular risk stratification 3.

Alpha-Blocker Co-administration

Patients must be stable on alpha-blocker therapy before initiating PDE5 inhibitors, and PDE5 inhibitors should start at the lowest dose 1. This precaution (not contraindication) reflects updated evidence showing symptomatic hypotension risk rather than absolute contraindication 7.

Drug Interactions

CYP3A4 Inhibitors (Major Pathway)

Potent inhibitors significantly increase sildenafil levels 1:

  • Ritonavir: 1000% (11-fold) increase in AUC - maximum 25 mg per 48 hours 1
  • Saquinavir: 210% increase in AUC 1
  • Ketoconazole/itraconazole: Expected to have greater effects than erythromycin 1
  • Erythromycin: 182% increase in exposure 1
  • Cimetidine: 56% increase 1

CYP3A4 inducers decrease sildenafil levels:

  • Rifampin and other strong inducers expected to cause significant decreases 1
  • Bosentan: 63% decrease in AUC 1

Minimal or No Clinically Significant Interactions

Clinical trial data showed no effect on sildenafil pharmacokinetics from 1:

  • CYP2C9 inhibitors (tolbutamide, warfarin)
  • CYP2D6 inhibitors (SSRIs, tricyclic antidepressants)
  • Thiazide and related diuretics
  • ACE inhibitors
  • Calcium channel blockers
  • Antacids (magnesium hydroxide/aluminum hydroxide)

Sildenafil is a weak inhibitor of multiple CYP isoforms (IC50 >150 µM), making it unlikely to affect other drugs 1.

Synergistic Effects

  • Statins and testosterone: May have synergistic effects with PDE5 inhibitors on sexual activity 7

Adverse Events Profile

Common Side Effects (Dose-Related)

The most frequent adverse events are transient, mild to moderate, and related to vasodilatory properties 2, 5:

  • Headache (most common across all PDE5 inhibitors)
  • Flushing (lowest with tadalafil) 2
  • Dyspepsia (lowest with avanafil; caused by gastroesophageal sphincter relaxation) 2, 5
  • Nasal congestion (most common AE for medium/high doses) 8
  • Visual disturbances
  • Myalgia and back pain (lowest with vardenafil and avanafil) 2

Comparative Adverse Event Rates

Recent real-world data from 132,100 patients showed 8:

  • Sildenafil: 35.0% overall AE rate
  • Tadalafil: 33.9% (similar to sildenafil)
  • Vardenafil: 47.4% (significantly higher)

Drug-specific differences 8:

  • Sildenafil causes more flushing than tadalafil (7.3% vs 2.3%)
  • Tadalafil causes more reflux than sildenafil (8.0% vs 5.3%)

Serious Adverse Events - Clinical Warnings

Visual changes: Stop all PDE5 inhibitors and seek immediate medical attention for sudden vision loss in one or both eyes - may indicate non-arteritic anterior ischemic optic neuropathy (NAION) 1. Risk is increased in those with prior NAION in one eye.

Hearing loss: Stop PDE5 inhibitors and seek prompt medical attention for sudden hearing decrease/loss, which may be accompanied by tinnitus and dizziness 1.

Priapism: Erections lasting >4 hours require immediate medical assistance; priapism (>6 hours) can cause permanent penile tissue damage and loss of potency 1.

Clinical Pearls and Common Pitfalls

Optimizing Efficacy

For PDE5 inhibitor "nonresponders," verify 3:

  1. Appropriate medication timing (taken 1 hour before activity for sildenafil)
  2. Adequate sexual stimulation (drug requires arousal to work)
  3. Proper dosing (may need titration to higher dose)

Education about these factors can restore effectiveness in many patients 3.

Special Populations

Diabetes and post-prostatectomy patients: Have more severe ED at baseline and respond less robustly to PDE5 inhibitors, though still show benefit 2.

Hypogonadal patients: Testosterone therapy in combination with PDE5 inhibitors may help nonresponders 3.

Emergency Management

If severe hypotension occurs after PDE5 inhibitor use 4:

  1. Aggressive fluid resuscitation (first step)
  2. Vasoactive drugs if needed
  3. Intraaortic balloon counterpulsation if necessary
  4. Never use nitrates - treat acute coronary syndrome according to guidelines but without nitrates

Patient Counseling

  • PDE5 inhibitors offer no protection against sexually transmitted diseases 1
  • Cannot be combined with other PDE5 inhibitors (including REVATIO for pulmonary hypertension) 1
  • Sexual activity itself carries cardiovascular risk in patients with pre-existing disease - discuss cardiac risk stratification 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.